Testing effectiveness (Phase 2)Study completedNCT05039099
What this trial is testing
Evaluate, Safety, Tolerability, Pharmacodynamic (PD) Markers and Pharmacokinetics (PK) of AP-101 in Participants With Amyotrophic Lateral Sclerosis (ALS)
Who this might be right for
Amyotrophic Lateral Sclerosis
AL-S Pharma 73